Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue under collaboration agreements	$ 20	$ 663
Operating expenses:
Research and development	6,552	5,423
General and administrative	12,181	2,339
Total operating expenses	18,733	7,762
Loss from operations	(18,713)	(7,099)
Other income (expense), net	3,752	(151)
Net loss	(14,961)	(7,250)
Change in unrealized loss on available-for-sale securities	(339)	0
Comprehensive loss	$ (15,300)	$ (7,250)
Earnings Per Share, Basic	$ (0.16)	$ (0.24)
Earnings Per Share, Diluted	$ (0.16)	$ (0.24)
Weighted Average Number of Shares Outstanding, Basic	94,227,313	30,369,413
Weighted Average Number of Shares Outstanding, Diluted	94,227,313	30,369,413